A double blind randomized controlled trial of post-operative low molecular weight heparin bridging therapy versus placebo bridging therapy for patients who are at high risk for arterial thromboembolism (PERIOP 2)
Latest Information Update: 02 Feb 2022
At a glance
- Drugs Dalteparin sodium (Primary)
- Indications Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms PERIOP 2
- 09 Jun 2021 Results (n=1471) assessing efficacy and safety of dalteparin postoperative bridging treatment versus placebo for patients with atrial fibrillation or mechanical heart valves when warfarin is temporarily interrupted for a planned procedure, published in the BMJ.
- 18 Feb 2020 Planned End Date changed from 1 Sep 2019 to 1 Dec 2020.
- 27 Feb 2019 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.